Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19870
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVallejo-Ardila, Dora L-
dc.contributor.authorFifis, Theodora-
dc.contributor.authorBurrell, Louise Men
dc.contributor.authorWalsh, Katrina-
dc.contributor.authorChristophi, Christopher-
dc.date2018-10-26-
dc.date.accessioned2018-11-26T00:51:13Z-
dc.date.available2018-11-26T00:51:13Z-
dc.date.issued2018-10-26-
dc.identifier.citationOncotarget 2018; 9(84): 35500-35511-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/19870-
dc.description.abstractRenin-angiotensin system inhibitors (RASi) have shown potential anti-tumor effects that may have a significant impact in cancer therapy. The components of the renin-angiotensin system (RAS) including both, conventional and alternative axis, appear to have contradictory effects on tumor biology. The mechanisms by which RASi impair tumor growth extend beyond their function of modulating tumor vasculature. The major focus of this review is to analyze other mechanisms by which RASi reprogram the tumor immune microenvironment. These involve impairing hypoxia and acidosis within the tumor stroma, regulating inflammatory signaling pathways and oxidative stress, modulating the function of the non-cellular components and immune cells, and regulating the cross-talk between kalli krein kinin system and RAS.-
dc.language.isoeng-
dc.subjectanti-tumor immunity-
dc.subjectkallikrein kinin system-
dc.subjectrenin-angiotensin system-
dc.subjecttumor microenvironment-
dc.titleRenin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity.-
dc.typeJournal Article-
dc.identifier.journaltitleOncotarget-
dc.identifier.affiliationDepartment of Cardiology, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.18632/oncotarget.26174-
dc.identifier.orcid0000-0003-1863-7539-
dc.identifier.pubmedid30464806-
dc.type.austinJournal Article-
dc.type.austinReview-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptSurgery-
crisitem.author.deptHepatopancreatobiliary Surgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.